In relapsed AML patients however, the combination of 5-Aza with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) significantly increased median overall survival compared to 5-Aza alone [13]. The gene discussed is CTLA4; the disease is acute myeloid leukemia.